98%
921
2 minutes
20
Introduction: The impact of pneumococcal conjugate vaccines (PCVs) on antimicrobial resistance (AMR) in Streptococcus pneumoniae (Spn) among Chinese children remains inadequately characterized. Evidence is also limited on the interaction between vaccination coverage and regional disparities in AMR patterns. This study aims to assess the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on nasopharyngeal carriage of Spn and antimicrobial nonsusceptibility to commonly used antibiotics among healthy children under five years of age in China.
Methods: In 2022, 737 pneumococci were isolated from 2333 healthy children recruited in 4 areas (Haikou, Wanning, Baisha, and Qiongzhong) in Hainan Province, China. Serotyping and antimicrobial susceptibility tests were performed. Participants were divided into 4 groups based on individual PCV13 vaccination history and the local vaccination coverage rates: vaccinated and unvaccinated groups in the high-coverage area (group VH & NVH), and vaccinated and unvaccinated groups in the low-coverage areas (group VL & NVL). Descriptive statistics and logistic regression analysis were used to assess the vaccine impacts.
Results: PCV13-vaccinated children exhibited significantly lower carriage rates of vaccine-type serotypes (VTs) compared to unvaccinated children: 6B (7.0 % vs. 2.7 %, P < 0.01), 6A (4.2 % vs. 1.2 %, P < 0.05), and 23F (2.2 % vs. 0.3 %, P < 0.05). The non-susceptibility rates to erythromycin, azithromycin, clindamycin, tetracycline, penicillin, and cefuroxime were 92.3 %, 87.5 %, 81.2 %, 91.2 %, 38.9 % and 64.7 %, respectively, resulting in 82.9 % of isolates being multidrug-resistant (MDR), especially to VTs (92.4 %). Isolates from the high PCV13 coverage area were less resistant to penicillin, cefuroxime, erythromycin, azithromycin, clindamycin and SXT, and were less MDR than isolates from the low PCV13 coverage areas.
Conclusions: Nasopharyngeal carriage of Spn was highly resistant to common clinical antibiotics. PCV13 vaccination significantly decreased VTs carriage and antimicrobial nonsusceptibility. These results suggest that the widespread use of PCVs is likely to substantially affect NP carriage and antimicrobial nonsusceptibility.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.vaccine.2025.127455 | DOI Listing |
Vaccine
September 2025
Mérieux Foundation, 17 Rue Bourgelat, 69002 Lyon, France. Electronic address:
Introduction: Streptococcus pneumoniae is a major cause of lower respiratory infections, especially in children under 5 years old. While pneumococcal conjugate vaccines (PCVs) have reduced disease burden in many countries, data from low- and middle-income countries are still limited. The objective of this prospective, hospital-based, cross -sectional study was to measure the prevalence of pneumococcal colonization and identify circulating serotypes among children <5 years and their caregivers in Cambodia and India.
View Article and Find Full Text PDFCell Host Microbe
August 2025
Division of Molecular Microbiology, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK. Electronic address:
Streptococcus pneumoniae colonizes human airways, where it acquires sugars from glycosylated mucins using glycoside hydrolases and sugar transport systems. This study identifies widespread nucleotide sequence variation in the promoter of a pneumococcal operon encoding a glycan scavenging system. We identify 78 promoter sequence patterns across 21,155 genomes, with variation clustered within a stretch of adenines, where mutations accumulate via strand slippage during DNA replication.
View Article and Find Full Text PDFVaccine
August 2025
Merck & Co., Inc., Rahway, NJ, USA. Electronic address:
To better inform pneumococcal immunization policies, ongoing surveillance for pneumococcal community-acquired pneumonia (CAP) is crucial. To estimate the serotype-specific CAP burden of pneumococcal disease following the introduction of a new 15-valent pneumococcal conjugate vaccine (PCV), V114, a 15-plex serotype-specific urine antigen detection (SSUAD) assay was developed as a tool for surveillance of Streptococcuspneumoniae serotypes. V114-017 (NCT03547167; EudraCT 2017-004915-38) was a phase 3 randomized controlled trial in which participants (18-49 years) received V114 or 13-valent PCV (PCV13; as an active comparator), followed 6 months later by 23-valent pneumococcal polysaccharide vaccine (PPSV23).
View Article and Find Full Text PDFJ Infect Dis
August 2025
Centre for the Evaluation of Vaccination, University of Antwerp, Wilrijk, Belgium.
Background: Tetanus, Diphtheria and acellular Pertussis (Tdap) vaccination during pregnancy blunts the infant humoral immune response following primary immunization with pneumococcal conjugate vaccines (PCVs). While this effect typically resolves after the booster dose for most vaccine serotypes, its impact on nasopharyngeal carriage of pneumococcal vaccine serotypes remains unclear.
Methods: A total of 3,298 nasopharyngeal swabs were collected from infants aged 6-30 months attending daycare centers in Belgium between 2018 and 2022, along with data on maternal Tdap vaccination status (clinicaltrials.
Front Microbiol
August 2025
Department of Urology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, China.
Objective: To investigate the distribution characteristics of methicillin-resistant (MRSA) infection in people living with HIV (PLWH), to analyse the risk factors of MRSA colonisation in the nasopharynx of PLWH, and to provide a scientific basis for the prevention of hospital-acquired MRSA infection in PLWH.
Methods: This study used a cross-sectional research design to analyse 1,100 PLWH attending the AIDS outpatient clinic of the People's Hospital of Dongyang City, Zhejiang Province, from January 2022 to December 2024. Nasal swabs were collected with informed consent, and epidemiological information was collected via questionnaire.